Jian Zhang, Yanchun Meng and colleagues assess the activity and safety of combining dalpiciclib with pyrotinib and endocrine therapy in patients receiving first- or second-line treatment for ER-positive and HER2-positive advanced breast cancer. This evidence concerns the gene ERBB2 and breast carcinoma.